-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $28

Benzinga·09/03/2026 20:52:07
语音播报
Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $77 to $28.